Similar results have been observed in clinical trials of p38 inhibitors in Crohn’s disease, cardiovascular disease, chronic obstructive pulmonary disease, cancer, and neurotic pain, where clinical efficacy was not achieved or sustained, and/or the study terminated due to adverse events62–68. This evidence concerns the gene MAPK14 and cancer.